Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

Stefanie Aust; Anna Bachmayr-Heyda; Petra Pateisky; Dan Cacsire Castillo-Tong; Silvia Darb-Esfahani; Carsten Denkert; Radoslav Chekerov; Jalid Sehouli; Sven Mahner; Toon Van Gorp; Ignace Vergote; Paul Speiser; Reinhard Horvat; Robert Zeillinger; Dietmar Pils

doi:10.1186/1476-4598-11-69

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

Stefanie Aust, Anna Bachmayr-Heyda, Petra Pateisky, Dan Cacsire Castillo-Tong, Silvia Darb-Esfahani, Carsten Denkert, Radoslav Chekerov, Jalid Sehouli, Sven Mahner, Toon Van Gorp, Ignace Vergote, Paul Speiser, Reinhard Horvat, Robert Zeillinger, Dietmar Pils^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

33 Citations (Web of Science)

Abstract

The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor ? (ER?) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ER? expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ER? in regard to clinicopathological parameters, chemotherapy response, and survival.Expressions of TRAP1 and ER? were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ER? was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ER? (p

Original language	English
Pages (from-to)	69
Journal	Molecular Cancer
Volume	11
DOIs	https://doi.org/10.1186/1476-4598-11-69
Publication status	Published - 14 Sep 2012

Keywords

TRAP1
Estrogen receptor
Immunohistochemistry
Prognosis
Ovarian cancer

Access to Document

10.1186/1476-4598-11-69

Cite this

Aust, S., Bachmayr-Heyda, A., Pateisky, P., Castillo-Tong, D. C., Darb-Esfahani, S., Denkert, C., Chekerov, R., Sehouli, J., Mahner, S., Van Gorp, T., Vergote, I., Speiser, P., Horvat, R., Zeillinger, R., & Pils, D. (2012). Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium. Molecular Cancer, 11, 69. https://doi.org/10.1186/1476-4598-11-69

@article{ef654098d72945f3b8d242e5ce4201d2,

title = "Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium",

abstract = "The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor ? (ER?) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ER? expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ER? in regard to clinicopathological parameters, chemotherapy response, and survival.Expressions of TRAP1 and ER? were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ER? was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ER? (p",

keywords = "TRAP1, Estrogen receptor, Immunohistochemistry, Prognosis, Ovarian cancer",

author = "Stefanie Aust and Anna Bachmayr-Heyda and Petra Pateisky and Castillo-Tong, {Dan Cacsire} and Silvia Darb-Esfahani and Carsten Denkert and Radoslav Chekerov and Jalid Sehouli and Sven Mahner and {Van Gorp}, Toon and Ignace Vergote and Paul Speiser and Reinhard Horvat and Robert Zeillinger and Dietmar Pils",

year = "2012",

month = sep,

day = "14",

doi = "10.1186/1476-4598-11-69",

language = "English",

volume = "11",

pages = "69",

journal = "Molecular Cancer",

issn = "1476-4598",

publisher = "BioMed Central Ltd",

}

Aust, S, Bachmayr-Heyda, A, Pateisky, P, Castillo-Tong, DC, Darb-Esfahani, S, Denkert, C, Chekerov, R, Sehouli, J, Mahner, S, Van Gorp, T, Vergote, I, Speiser, P, Horvat, R, Zeillinger, R & Pils, D 2012, 'Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium', Molecular Cancer, vol. 11, pp. 69. https://doi.org/10.1186/1476-4598-11-69

TY - JOUR

T1 - Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

AU - Aust, Stefanie

AU - Bachmayr-Heyda, Anna

AU - Pateisky, Petra

AU - Castillo-Tong, Dan Cacsire

AU - Darb-Esfahani, Silvia

AU - Denkert, Carsten

AU - Chekerov, Radoslav

AU - Sehouli, Jalid

AU - Mahner, Sven

AU - Van Gorp, Toon

AU - Vergote, Ignace

AU - Speiser, Paul

AU - Horvat, Reinhard

AU - Zeillinger, Robert

AU - Pils, Dietmar

PY - 2012/9/14

Y1 - 2012/9/14

N2 - The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor ? (ER?) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ER? expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ER? in regard to clinicopathological parameters, chemotherapy response, and survival.Expressions of TRAP1 and ER? were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ER? was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ER? (p

AB - The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor ? (ER?) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ER? expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ER? in regard to clinicopathological parameters, chemotherapy response, and survival.Expressions of TRAP1 and ER? were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ER? was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ER? (p

KW - TRAP1

KW - Estrogen receptor

KW - Immunohistochemistry

KW - Prognosis

KW - Ovarian cancer

U2 - 10.1186/1476-4598-11-69

DO - 10.1186/1476-4598-11-69

M3 - Article

VL - 11

SP - 69

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

ER -